Related Experiment Video
Updated: Jun 8, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
Nephrotic syndrome induced by pamidronate
M A G J ten Dam1, L B Hilbrands, J F M Wetzels
1Department of Internal Medicine, Canisius Wilhelmina Hospital, P.O. Box 9015, 6500, Nijmegen, The Netherlands. m.t.dam@cwz.nl
Intravenous pamidronate can cause nephrotic syndrome and kidney damage, specifically collapsing focal segmental glomerulosclerosis (FSGS). Monitoring kidney function is crucial during bisphosphonate therapy, especially in patients with pre-existing kidney issues.
Area of Science:
- Nephrology
- Pharmacology
- Pathology
Background:
- Bisphosphonates, particularly intravenous pamidronate, are widely used for bone-related conditions.
- Potential renal toxicity associated with bisphosphonate therapy requires careful consideration.
Observation:
- Two patients receiving intravenous pamidronate developed nephrotic syndrome and declining renal function.
- Renal biopsies in both patients revealed collapsing focal segmental glomerulosclerosis (FSGS).
Findings:
- Discontinuation of pamidronate led to recovery in one patient, while the other required dialysis.
- The study highlights collapsing FSGS as a serious complication of pamidronate treatment.
Implications:
- Regular monitoring of urinary protein excretion and renal function is essential for patients on long-term intravenous bisphosphonates.
- Caution is advised when administering bisphosphonates to patients with estimated GFR below 30 ml/min due to increased risk of nephrotoxicity.
Related Concept Videos
Nephrotic Syndrome I : Introduction
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome III : Nursing Management
Chronic Kidney Disease II: Clinical Manifestations
Nephrons
Chronic Kidney Disease III: Interprofessional Care
